1Hassan First University of Settat, Higher Institute of Health Sciences, Laboratory of Health Sciences and Technologies, Settat, Morocco
2Science and Technology Team, Higher School of Education and Training, Chouaîb Doukkali University of El Jadida, El Jadida, Morocco
© 2024 Korea Disease Control and Prevention Agency.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Ethics Approval
Not applicable.
Conflicts of Interest
The authors have no conflicts of interest to declare.
Funding
None.
Availability of Data
All data generated or analyzed during this study are included in this published article. For other data, these may be requested through the corresponding author.
Authors’ Contributions
Conceptualization: YI, MC, ES; Data curation: YI, MG; Formal analysis: YI, MG; Investigation: YI, NAW, MA, NE, YM, KB, MG, AI; Methodology: YI; Project administration: YI, MC, ES; Resources: YI; Software: YI, MG; Supervision: MC, ES; Validation: ES, MC; Visualization: NE; Writing–original draft: YI; Writing–review & editing: all authors. All authors read and approved the final manuscript.
Study | Year | Principal predictive factors of outcome | Study design | Location | TBI degree | Outcome assessment tool | Follow-up period (mo) | Sample size | Quality score (NOS) |
---|---|---|---|---|---|---|---|---|---|
Kokkinou et al. [35] | 2020 | Age | Longitudinal | Cyprus | Moderate to severe TBI | GOS-E and QOLIBRI-OS | 6 | 203 | Good |
Latronico et al. [36] | 2020 | Posttraumatic cerebral infarction | Prospective | Italy | Moderate and severe TBI | GOS | 6 | 143 | Good |
Bennis et al. [24] | 2020 | CRASH model and combined model | Retrospective | Netherlands | Severe TBI | GOS | 6 | 45 | Fair |
Vijapur et al. [37] | 2021 | Innate immunity, soluble molecules, chemokines | Prospective | USA | Moderate to severe TBI | GOS and DRS | 6–12 | 221 | Fair |
Dullaert et al. [51] | 2020 | CRASH model | Retrospective | Belgium | All severities | GOS | 6 | 417 | Fair |
Jiang et al. [25] | 2020 | ICP, caspase 3 | Prospective | China | Severe TBI | GOS | 6 | 45 P and 25 C | Good |
Thelin et al. [47] | 2019 | Age, glucose level, CT scan results, UCH-L1, GFAP, S100B | Prospective | Sweden | All severities | GOS | 12 | 172 | Good |
Charry et al. [48] | 2019 | CT scan results, IMPACT model, CRASH model | Retrospective | Colombia | All severities | GOS | 6 | 309 | Fair |
Hellstrom et al. [34] | 2017 | Brain imaging data, clinical data | Prospective | Norway | Mild TBI | GOS-E, RPQ, PHQ-9 | 12 | 147 | Good |
Riemann et al. [52] | 2020 | PRx and 20-LPRx | Retrospective | Germany | All severities | GOS | 6 | 855 | Fair |
Khaki et al. [43] | 2021 | IMPACT base model, CT scan results | Retrospective | Sweden | All severities | GOS | 12 | 158 | Fair |
Thelin et al. [26] | 2017 | CT scan results | Prospective | Sweden and Finland | Severe TBI | GOS | 12 | 1115 | Good |
Lindblad et al. [27] | 2021 | QA, cerebrospinal fluid, serum | Prospective | Sweden | Severe TBI | GOS | 6–12 | 90 P and 15 C | Good |
Chen et al. [28] | 2018 | Age, GCS, glucose, hypoxia, pupillary reactivity, neurological deterioration, seizure, SpO2, CT scan results, mechanical ventilation, intracranial surgery, NLR | Retrospective | China | Severe TBI | GOS | 12 | 688 | Fair |
Petkus et al. [29] | 2020 | Age, duration of LCAI (PRx>0.5), glucose, GCS | Retrospective | Lithuania | Severe TBI | GOS | 6 | 81 | Fair |
Bilgi et al. [38] | 2021 | Age, time from injury to surgery, GCS, pupillary reactivity, hemoglobin, glucose, TLC, INR, blood transfusion, decompressive craniectomy | Prospective | India | Moderate and severe isolated head injury | GOS-E | 6 | 96 | Good |
Bendinelli et al. [30] | 2017 | GCS, injury severity score, days in ICU, CT scan results | Prospective | Australia | Severe TBI | GOS-E | 6 | 50 | Good |
Tolonen et al. [31] | 2018 | None | Retrospective | Finland | Severe TBI | GOS | 6 and 12 | 28 | Good |
Gritti et al. [39] | 2019 | Oxford Handicap Scale score, posttraumatic cerebral infarction, posttraumatic hydrocephalus, hygroma, length of stay, invasive ventilation | Retrospective | Italy | Moderate and severe | GOS-E | 12 | 193 | Fair |
Dolmans et al. [32] | 2020 | Age, hematocrit, hemoglobin, red blood cells, sodium, blood urea nitrogen, INR, prothrombin time | Retrospective | USA | Severe TBI | GOS | 3 | 255 | Fair |
Bonow et al. [33] | 2018 | Age, race, education, mechanism of injury, motor score, pupillary reactivity, Abbreviated Injury Scale Head score, CT scan results, initial cerebral perfusion pressure | Prospective | Bolivia and Ecuador | Severe TBI | GOS-E | 6 | 550 | Good |
Li et al. [49] | 2018 | Monocyte level | Observational and non-interventional | China | All severities | GOS-E | 6 | 141 | Good |
Lindblad et al. [42] | 2018 | Age, GCS, pupil responsiveness, CT scan results, SpO2, arachidonic acid receptor, thrombin receptor, activated partial thromboplastin time, platelet transfusion, COX inhibitor treatment | Retrospective observational | Sweden | All severities | GOS | 12 | 178 | Fair |
Palekar et al. [44] | 2021 | CT scan results, GCS, pupillary reactivity | Prospective | India | All severities | GOS | 1, 3, and 6 | 108 | Good |
Yao et al. [40] | 2017 | Age, GCS, motor score, pupillary reactivity, mass lesions, mass lesion size, intraventricular hemorrhage, suprasellar cisterns | Retrospective cohort | China | Moderate, severe, and complicated mild | GOS | 3–6 | 302 | Fair |
Lagerstedt et al. [45] | 2020 | NA | Prospective, observational | Finland | All severities | GOS-E | 6–12 | 88 | Good |
Zhao et al. [50] | 2019 | Age, mechanism of injury, pupillary reactivity, GCS, CT scan results, coagulopathy, WBC count, neutrophil ratio, lymphocyte ratio, NLR | Retrospective, observational | China | All severities | GOS | 6 | 1291 | Fair |
Svedung Wettervik et al. [46] | 2019 | Age, GCS, pupillary reactivity, CT scan results, arterial blood pressure | Retrospective | Sweden | All severities | GOS-E | 6 | 362 | Fair |
Al-Hassani et al. [41] | 2018 | Age | Retrospective observational | Qatar | Moderate to severe TBI | RLA, FIM, AFG, disability scale | 3 | 201 | Fair |
TBI, traumatic brain injury; NOS, Newcastle-Ottawa scale; GOS-E, Glasgow outcome scale-extended; QOLIBRI-OS, quality of life after traumatic brain injury-overall scale; GOS, Glasgow outcome scale; DRS, disability rating scale; CRASH, Corticosteroid Randomization after Significant Head Injury; ICP, intracranial pressure; P, patients with TBI; C, controls; CT, computed tomography; UCH-L1, ubiquitin carboxy-terminal hydrolase L1; GFAP, glial fibrillary acidic protein; S100B, S100 calcium-binding protein B; PRx, pressure reactivity index; LPRx, long pressure reactivity index; IMPACT, International Mission for Prognosis and Clinical Trial; RPQ, Rivermead Post-Concussion Symptoms Questionnaire; PHQ-9, Patient Health Questionnaire-9; QA, CSF-serum albumin quotient; GCS, Glasgow coma scale; SpO2, blood oxygen saturation; NLR, neutrophil-to-lymphocyte ratio; LCAI, longest cerebrovascular autoregulation impairment; TLC, total leukocyte count; INR, international normalized ratio; ICU, intensive care unit; COX, cyclooxygenase; NA, not applicable; WBC, white blood cell; RLA, Rancho Los Amigos; FIM, functional independence measure; AFG, absolute functional gain.
Variable | Studies (n) | Proportion (%) | 95% CI |
Test for heterogeneity |
|
---|---|---|---|---|---|
I2 (%) | p | ||||
Sex [25,27,28,30,35,37,41,42,45,46,49] | |||||
Male | 11 | 47.098 | 34.423–59.966 | 97.62 | <0.001 |
Female | 11 | 55.355 | 39.858–70.336 | 94.58 | <0.001 |
GCS [40,44,45] | |||||
13–15 | 3 | 6.888 | 2.535–13.161 | 0.00 | 0.535 |
9–12 | 3 | 22.361 | 5.599–46.087 | 85.83 | <0.001 |
3–8 | 3 | 58.584 | 32.838–82.035 | 91.91 | <0.001 |
ISS [33,45] | |||||
0 to 15 | 2 | 35.317 | 5.741–73.566 | 96.50 | <0.001 |
16 or more | 2 | 60.299 | 40.686–78.327 | 72.92 | 0.055 |
Motor score [33,40,46] | |||||
1–2 | 3 | 57.074 | 14.514–93.932 | 98.25 | <0.001 |
3–6 | 3 | 51.431 | 39.643–63.139 | 91.50 | <0.001 |
Marshall score | |||||
I or II [31,33,45,49] | 4 | 34.433 | 14.880–57.252 | 84.67 | 0.002 |
III or IV [31,33,45,49] | 4 | 54.197 | 39.698–68.343 | 65.48 | 0.034 |
V or VI [28,31,33,45,49] | 5 | 62.488 | 50.174–74.033 | 82.52 | <0.001 |
Abnormal cisterns [28,33,40] | 3 | 65.713 | 48.943–80.675 | 96.45 | <0.001 |
ICP >20 mmHg [33,49] | 2 | 52.915 | 31.329–73.944 | 68.07 | 0.077 |
Midline shift of 5 mm or more [28,33,44] | 3 | 63.063 | 48.815–76.235 | 87.92 | <0.001 |
Hypotension present [33,49] | 2 | 71.004 | 60.059–80.834 | 0.00 | 0.353 |
Hypoxia present [28,49] | 2 | 86.785 | 77.704–93.767 | 0.00 | 0.406 |
Blood transfusion [38,49] | 2 | 70.278 | 35.585–95.170 | 92.01 | <0.001 |
Mechanical ventilation [28,49] | 2 | 90.016 | 38.859–93.648 | 98.25 | <0.001 |
Surgery | |||||
Craniectomy [38,46,49] | 3 | 62.456 | 43.356–79.732 | 74.71 | 0.019 |
Craniotomy [30,46,49] | 3 | 50.511 | 32.933–68.023 | 73.51 | 0.023 |
Pupillary reaction | |||||
Both reacting [33,40,44,49,50] | 5 | 31.790 | 18.228–47.153 | 96.14 | <0.001 |
Neither reacting [33,38,40,44,49,50] | 6 | 71.647 | 53.901–86.469 | 87.95 | <0.001 |
One reacting [33,38,40,44,49,50] | 6 | 59.451 | 51.214–67.428 | 32.05 | 0.195 |
Mechanism | |||||
Violence [31,49,50] | 3 | 30.471 | 18.629–43.801 | 9.34 | 0.332 |
Road [31,33,49,50] | 4 | 47.120 | 28.696–65.960 | 96.28 | <0.001 |
Fall [31,33,49,50] | 4 | 47.923 | 23.246–73.155 | 94.23 | <0.001 |
Others [31,33,49,50] | 4 | 28.353 | 9.265–52.835 | 83.35 | <0.001 |
Type of injury | |||||
DAI [30,44,50] | 3 | 65.987 | 53.922–77.082 | 0.00 | 0.649 |
Epidural hematoma [40,49,50] | 3 | 24.914 | 18.079–32.446 | 50.09 | 0.135 |
Skull fracture [33,50] | 2 | 39.813 | 9.429–75.544 | 98.55 | <0.001 |
Intracerebral hematoma [40,44] | 2 | 35.885 | 19.776–53.833 | 55.92 | 0.132 |
Intraventricular hemorrhage [33,40] | 2 | 76.586 | 59.685–89.971 | 47.48 | 0.168 |
Subarachnoid hemorrhage [28,33,44,49,50] | 5 | 49.232 | 29.013–69.584 | 98.22 | <0.001 |
Subdural hematoma [40,44,49,50] | 4 | 44.043 | 37.108–51.097 | 53.49 | 0.092 |
Inclusion criteria | Exclusion criteria |
---|---|
All language papers published in peer-reviewed journals | Article reviews, book chapters, and case reports |
Articles published between 2017 and 2021 | Studies investigating nonhuman subjects |
TBI severity of mild to severe | Studies including children |
Studies investigating functional outcomes | Sample sizes of fewer than 20 participants |
Outcomes categorized into favorable and unfavorable | Studies investigating outcomes other than favorable and/or unfavorable |
Studies including only a specific group of people or only a subgroup of TBI patients | |
Articles that do not mention the site of the study | |
Articles that do not mention the severity of TBI | |
Outcomes at less than 3 months | |
Penetrating TBI |
Study | Year | Principal predictive factors of outcome | Study design | Location | TBI degree | Outcome assessment tool | Follow-up period (mo) | Sample size | Quality score (NOS) |
---|---|---|---|---|---|---|---|---|---|
Kokkinou et al. [35] | 2020 | Age | Longitudinal | Cyprus | Moderate to severe TBI | GOS-E and QOLIBRI-OS | 6 | 203 | Good |
Latronico et al. [36] | 2020 | Posttraumatic cerebral infarction | Prospective | Italy | Moderate and severe TBI | GOS | 6 | 143 | Good |
Bennis et al. [24] | 2020 | CRASH model and combined model | Retrospective | Netherlands | Severe TBI | GOS | 6 | 45 | Fair |
Vijapur et al. [37] | 2021 | Innate immunity, soluble molecules, chemokines | Prospective | USA | Moderate to severe TBI | GOS and DRS | 6–12 | 221 | Fair |
Dullaert et al. [51] | 2020 | CRASH model | Retrospective | Belgium | All severities | GOS | 6 | 417 | Fair |
Jiang et al. [25] | 2020 | ICP, caspase 3 | Prospective | China | Severe TBI | GOS | 6 | 45 P and 25 C | Good |
Thelin et al. [47] | 2019 | Age, glucose level, CT scan results, UCH-L1, GFAP, S100B | Prospective | Sweden | All severities | GOS | 12 | 172 | Good |
Charry et al. [48] | 2019 | CT scan results, IMPACT model, CRASH model | Retrospective | Colombia | All severities | GOS | 6 | 309 | Fair |
Hellstrom et al. [34] | 2017 | Brain imaging data, clinical data | Prospective | Norway | Mild TBI | GOS-E, RPQ, PHQ-9 | 12 | 147 | Good |
Riemann et al. [52] | 2020 | PRx and 20-LPRx | Retrospective | Germany | All severities | GOS | 6 | 855 | Fair |
Khaki et al. [43] | 2021 | IMPACT base model, CT scan results | Retrospective | Sweden | All severities | GOS | 12 | 158 | Fair |
Thelin et al. [26] | 2017 | CT scan results | Prospective | Sweden and Finland | Severe TBI | GOS | 12 | 1115 | Good |
Lindblad et al. [27] | 2021 | QA, cerebrospinal fluid, serum | Prospective | Sweden | Severe TBI | GOS | 6–12 | 90 P and 15 C | Good |
Chen et al. [28] | 2018 | Age, GCS, glucose, hypoxia, pupillary reactivity, neurological deterioration, seizure, SpO2, CT scan results, mechanical ventilation, intracranial surgery, NLR | Retrospective | China | Severe TBI | GOS | 12 | 688 | Fair |
Petkus et al. [29] | 2020 | Age, duration of LCAI (PRx>0.5), glucose, GCS | Retrospective | Lithuania | Severe TBI | GOS | 6 | 81 | Fair |
Bilgi et al. [38] | 2021 | Age, time from injury to surgery, GCS, pupillary reactivity, hemoglobin, glucose, TLC, INR, blood transfusion, decompressive craniectomy | Prospective | India | Moderate and severe isolated head injury | GOS-E | 6 | 96 | Good |
Bendinelli et al. [30] | 2017 | GCS, injury severity score, days in ICU, CT scan results | Prospective | Australia | Severe TBI | GOS-E | 6 | 50 | Good |
Tolonen et al. [31] | 2018 | None | Retrospective | Finland | Severe TBI | GOS | 6 and 12 | 28 | Good |
Gritti et al. [39] | 2019 | Oxford Handicap Scale score, posttraumatic cerebral infarction, posttraumatic hydrocephalus, hygroma, length of stay, invasive ventilation | Retrospective | Italy | Moderate and severe | GOS-E | 12 | 193 | Fair |
Dolmans et al. [32] | 2020 | Age, hematocrit, hemoglobin, red blood cells, sodium, blood urea nitrogen, INR, prothrombin time | Retrospective | USA | Severe TBI | GOS | 3 | 255 | Fair |
Bonow et al. [33] | 2018 | Age, race, education, mechanism of injury, motor score, pupillary reactivity, Abbreviated Injury Scale Head score, CT scan results, initial cerebral perfusion pressure | Prospective | Bolivia and Ecuador | Severe TBI | GOS-E | 6 | 550 | Good |
Li et al. [49] | 2018 | Monocyte level | Observational and non-interventional | China | All severities | GOS-E | 6 | 141 | Good |
Lindblad et al. [42] | 2018 | Age, GCS, pupil responsiveness, CT scan results, SpO2, arachidonic acid receptor, thrombin receptor, activated partial thromboplastin time, platelet transfusion, COX inhibitor treatment | Retrospective observational | Sweden | All severities | GOS | 12 | 178 | Fair |
Palekar et al. [44] | 2021 | CT scan results, GCS, pupillary reactivity | Prospective | India | All severities | GOS | 1, 3, and 6 | 108 | Good |
Yao et al. [40] | 2017 | Age, GCS, motor score, pupillary reactivity, mass lesions, mass lesion size, intraventricular hemorrhage, suprasellar cisterns | Retrospective cohort | China | Moderate, severe, and complicated mild | GOS | 3–6 | 302 | Fair |
Lagerstedt et al. [45] | 2020 | NA | Prospective, observational | Finland | All severities | GOS-E | 6–12 | 88 | Good |
Zhao et al. [50] | 2019 | Age, mechanism of injury, pupillary reactivity, GCS, CT scan results, coagulopathy, WBC count, neutrophil ratio, lymphocyte ratio, NLR | Retrospective, observational | China | All severities | GOS | 6 | 1291 | Fair |
Svedung Wettervik et al. [46] | 2019 | Age, GCS, pupillary reactivity, CT scan results, arterial blood pressure | Retrospective | Sweden | All severities | GOS-E | 6 | 362 | Fair |
Al-Hassani et al. [41] | 2018 | Age | Retrospective observational | Qatar | Moderate to severe TBI | RLA, FIM, AFG, disability scale | 3 | 201 | Fair |
Variable | Studies (n) | Proportion (%) | 95% CI | Test for heterogeneity |
|
---|---|---|---|---|---|
I2 (%) | p | ||||
Sex [25,27,28,30,35,37,41,42,45,46,49] | |||||
Male | 11 | 47.098 | 34.423–59.966 | 97.62 | <0.001 |
Female | 11 | 55.355 | 39.858–70.336 | 94.58 | <0.001 |
GCS [40,44,45] | |||||
13–15 | 3 | 6.888 | 2.535–13.161 | 0.00 | 0.535 |
9–12 | 3 | 22.361 | 5.599–46.087 | 85.83 | <0.001 |
3–8 | 3 | 58.584 | 32.838–82.035 | 91.91 | <0.001 |
ISS [33,45] | |||||
0 to 15 | 2 | 35.317 | 5.741–73.566 | 96.50 | <0.001 |
16 or more | 2 | 60.299 | 40.686–78.327 | 72.92 | 0.055 |
Motor score [33,40,46] | |||||
1–2 | 3 | 57.074 | 14.514–93.932 | 98.25 | <0.001 |
3–6 | 3 | 51.431 | 39.643–63.139 | 91.50 | <0.001 |
Marshall score | |||||
I or II [31,33,45,49] | 4 | 34.433 | 14.880–57.252 | 84.67 | 0.002 |
III or IV [31,33,45,49] | 4 | 54.197 | 39.698–68.343 | 65.48 | 0.034 |
V or VI [28,31,33,45,49] | 5 | 62.488 | 50.174–74.033 | 82.52 | <0.001 |
Abnormal cisterns [28,33,40] | 3 | 65.713 | 48.943–80.675 | 96.45 | <0.001 |
ICP >20 mmHg [33,49] | 2 | 52.915 | 31.329–73.944 | 68.07 | 0.077 |
Midline shift of 5 mm or more [28,33,44] | 3 | 63.063 | 48.815–76.235 | 87.92 | <0.001 |
Hypotension present [33,49] | 2 | 71.004 | 60.059–80.834 | 0.00 | 0.353 |
Hypoxia present [28,49] | 2 | 86.785 | 77.704–93.767 | 0.00 | 0.406 |
Blood transfusion [38,49] | 2 | 70.278 | 35.585–95.170 | 92.01 | <0.001 |
Mechanical ventilation [28,49] | 2 | 90.016 | 38.859–93.648 | 98.25 | <0.001 |
Surgery | |||||
Craniectomy [38,46,49] | 3 | 62.456 | 43.356–79.732 | 74.71 | 0.019 |
Craniotomy [30,46,49] | 3 | 50.511 | 32.933–68.023 | 73.51 | 0.023 |
Pupillary reaction | |||||
Both reacting [33,40,44,49,50] | 5 | 31.790 | 18.228–47.153 | 96.14 | <0.001 |
Neither reacting [33,38,40,44,49,50] | 6 | 71.647 | 53.901–86.469 | 87.95 | <0.001 |
One reacting [33,38,40,44,49,50] | 6 | 59.451 | 51.214–67.428 | 32.05 | 0.195 |
Mechanism | |||||
Violence [31,49,50] | 3 | 30.471 | 18.629–43.801 | 9.34 | 0.332 |
Road [31,33,49,50] | 4 | 47.120 | 28.696–65.960 | 96.28 | <0.001 |
Fall [31,33,49,50] | 4 | 47.923 | 23.246–73.155 | 94.23 | <0.001 |
Others [31,33,49,50] | 4 | 28.353 | 9.265–52.835 | 83.35 | <0.001 |
Type of injury | |||||
DAI [30,44,50] | 3 | 65.987 | 53.922–77.082 | 0.00 | 0.649 |
Epidural hematoma [40,49,50] | 3 | 24.914 | 18.079–32.446 | 50.09 | 0.135 |
Skull fracture [33,50] | 2 | 39.813 | 9.429–75.544 | 98.55 | <0.001 |
Intracerebral hematoma [40,44] | 2 | 35.885 | 19.776–53.833 | 55.92 | 0.132 |
Intraventricular hemorrhage [33,40] | 2 | 76.586 | 59.685–89.971 | 47.48 | 0.168 |
Subarachnoid hemorrhage [28,33,44,49,50] | 5 | 49.232 | 29.013–69.584 | 98.22 | <0.001 |
Subdural hematoma [40,44,49,50] | 4 | 44.043 | 37.108–51.097 | 53.49 | 0.092 |
TBI, traumatic brain injury.
TBI, traumatic brain injury; NOS, Newcastle-Ottawa scale; GOS-E, Glasgow outcome scale-extended; QOLIBRI-OS, quality of life after traumatic brain injury-overall scale; GOS, Glasgow outcome scale; DRS, disability rating scale; CRASH, Corticosteroid Randomization after Significant Head Injury; ICP, intracranial pressure; P, patients with TBI; C, controls; CT, computed tomography; UCH-L1, ubiquitin carboxy-terminal hydrolase L1; GFAP, glial fibrillary acidic protein; S100B, S100 calcium-binding protein B; PRx, pressure reactivity index; LPRx, long pressure reactivity index; IMPACT, International Mission for Prognosis and Clinical Trial; RPQ, Rivermead Post-Concussion Symptoms Questionnaire; PHQ-9, Patient Health Questionnaire-9; QA, CSF-serum albumin quotient; GCS, Glasgow coma scale; SpO2, blood oxygen saturation; NLR, neutrophil-to-lymphocyte ratio; LCAI, longest cerebrovascular autoregulation impairment; TLC, total leukocyte count; INR, international normalized ratio; ICU, intensive care unit; COX, cyclooxygenase; NA, not applicable; WBC, white blood cell; RLA, Rancho Los Amigos; FIM, functional independence measure; AFG, absolute functional gain.
TBI, traumatic brain injury; CI, confidence interval; GCS, Glasgow coma scale; ISS, injury severity score; ICP, intracranial pressure; DAI, diffuse axonal injury.